poisar

Stocks · News reference

West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum

Vandana Singh

West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

WST
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

    Cencora's U.S. Healthcare Solutions business demonstrated accelerating momentum with 5% revenue growth and 16% operating income growth in Q3, driven by specialty strength and OneOncology's performance. However, the company faces headwinds from manufacturer list-price reductions, the pending MWI divestiture expected to create a $150 million earnings impact, and regulatory uncertainty around 340B and ASP rules. GLP-1 growth and international operations provide diversification opportunities.

    CORGMEDVCYTWST
  2. Na

    TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences

    10x Genomics secured a favorable jury verdict against Parse Biosciences (a Qiagen subsidiary), winning $4.8M in damages for willful patent infringement on three single-cell analysis patents. The jury upheld all three patents' validity. 10x Genomics plans to seek enhanced damages, attorney fees, and a permanent U.S. injunction in post-trial proceedings. Despite the legal win, TXG shares fell over 5% following the announcement.

    TXGQGENGMEDWST
  3. Na

    Veeva Systems Q2 Earnings and Revenues Beat Estimates, Stock Up

    Veeva Systems (VEEV) reported Q2 fiscal 2027 adjusted EPS of $2.35, up 18.1% YoY and beating consensus by 5.9%, with revenues rising 17.6% to $928 million. The company raised its fiscal 2027 revenue guidance to $3.682-$3.687 billion and EPS to $9.21. Vault CRM momentum continued with over 180 customers live including five top 20 biopharmas, while the company advanced its AI strategy with Veeva Falcon.

    VEEVGMEDWSTCOO